Caroline Seymour

In an interview with Lt Col Yovanni Casablanca, MD, discussed the incorporation of new treatments into the cervical cancer paradigm and provided insight into the necessity of inclusive research with novel therapies.

An overall survival improvement for the combination of durvalumab and tremelimumab has been reported by the HIMALAYA clinical trial lead investigator.

Although cytokine release syndrome can occur in patients treated with APVO436, the event can be managed with steroids without adversely affecting treatment.

With an increase in genomic testing for colorectal cancer, new targeted treatments have also been developed to treat patients with specific disease characteristics.

Polatuzumab vedotin-piiq added to the R-CHOP regimen elicited a high progession-free survival rate in patients with newly-diagnosed diffuse large B-cell lymphoma.

Findings from the phase 3 ASCEMBL trial showed a consistent improvement in major molecular response rate and depth of response without any new or worsening adverse effects when treating with asciminib versus bosutinib in patients with chronic-phase chronic myeloid leukemia.

In an analysis of the phase 3 GLOW study, data showed promise for the use of ibrutinib/venetoclax in the frontline setting.

A pooled analysis of results from the randomized phase 2 SAFIR02_BREAST and SAFIR-PI3K trials show promise for the use of multigene sequencing to select targeted therapy for metastatic breast cancer.

Most patients with advanced HCC have resistance to PD-1 monotherapy. In other cancers, response to PD-1 inhibitors has been associated with an inflamed microenvironment with effector T cells and active IFN-α signaling.

In patients with HER2-positive, metastatic colorectal cancer, fam-trastuzumab deruxtecan-nxki led to improved responses in patients with higher HER2 expression at baseline, whereas responses were seen irrespective of RAS- and PIK3CA mutation status and blood tumor mutational burden levels.

A safety analysis from the phase 3 ARAMIS trial showed that tolerability with darolutamide was comparable with that of placebo in patients with nonmetastatic castration-resistant prostate cancer.

Tisotumab vedotin elicited significant responses without prohibitive toxicity in combination with carboplatin as frontline therapy, as well as in combination with pembrolizumab as second- or third-line therapy in patients with recurrent or metastatic cervical cancer.

Mobocertinib displayed a manageable safety profile across 40-mg, 120-mg, and 160-mg dose cohorts, leading to the determination of 160 mg as the maximum tolerated dose and recommended phase 2 dose for further study in Japanese patients with non–small cell lung cancer.

Multiple new targets are being researched for the treatment of chronic lymphocytic leukemia, and experts a particularly excited about novel BTK inhibitors and cellular therapies.

A study has shown that high interferon signaling and expression of MHC-II related genes can predict response to therapy is patients with advanced heptocellular carcinoma being treated for the first time.

Adjuvant treatment with atezolizumab led to a significant improvement in disease-free survival versus supportive care in patients with PD-L1–positive non–small cell lung cancer.

Although the genetic makeup of biliary tract cancer is rich, only recently has the field been able to show the benefit of treating patients with effective targeted agents, in the advanced setting.

Regardless of age the combination of ribociclib and endocrine therapy led to improved overall survival in pre- or postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer.

A frontline regimen nivolumab, ipilimumab, and 2 cycles of chemotherapy yielded an improvement in overall survival versus chemotherapy alone in patients with advanced non–small cell lung cancer. The benefit was observed regardless of tumor mutational burden status in the tissue or blood.

Subgroup analyses from the the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials show that achievement of transfusion independence by the 24th week of treatment is associated with an improvement in overall survival compared with continued transfusion dependence at that time point.

Based on a systematic review and meta-analysis , investigators say allogeneic hematopoietic cell transplant should be considered a standard of care option for patients with high-risk myelofibrosi.

In the phase 2 ELARA trial, treatment with the autologous CD19-directed chimeric antigen receptor T-cell therapy, tisagenlecleucel, achieved a high response rate that appeared durable, in patients with relapsed/refractory follicular lymphoma.

Pediatric patients with advanced RET-altered solid tumors showed preliminary efficacy with selpercatinib, according to data presented at the 2021 ASCO Annual Meeting.

Compared to fulvestrant alone, venetoclax and fulvestrant did not improve overall outcomes in patients with locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer who had previously received a CDK4/6 inhibitor.

According to results from the phase 1/2 and phase 2 ALTA trials, brigatinib demonstrated sustained long-term responses and survival in patients with crizotinib-refractory ALK-positive non–small cell lung cancer.

Mantle cell lymphoma cell lines with intrinsic resistance to BTK inhibitors displayed anti-tumor activity on treatment with tazemetostat as monotherapy or in combination with zanubrutinib, according to data from a preclinical analysis.

For patients with PD-L1 positive non-small cell lung cancer, qdjuvant treatment with atezolizumab (Tecentriq) led to a significant improvement in disease-free survival (DFS) vs best supportive care.

CA-125 surveillance alone could be used to detect disease progression in patients with advanced ovarian cancer and an abnormal CA-125 level at the beginning of frontline maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin), according to an analysis from the phase 3 PAOLA-1 that was presented at the SGO 2021 Annual Meeting on Women’s Cancer.

In with EGFR-mutant non–small cell lung cancer and brain metastases, oral osimertinib achieved rapid, high, and uniform brain exposure which was followed reduction in total brain metastases volume, according to results from the phase 1 ODIN-BM study.

Patritumab deruxtecan demonstrated early and clinically meaningful activity in pretreated patients with metastatic or unresectable EGFR-mutant non–small cell lung cancer in the results of a phase 1 trial that were presented during the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore.